drugset / Trial / NCT03606408
Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is the evaluation of long-term safety of osilodrostat in patients who have already received osilodrostat treatment in a previous Global Novartis-sponsored trial and who, based on investigators' judgement, will continue benefiting with its administration.
Timeline
- Start
- 2018-10-05
- Primary completion
- 2023-11-16
- Completion
- 2023-11-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | osilodrostat | Small molecule | 1 mg | Oral |
| Subject | osilodrostat | Small molecule | 5 mg | Oral |
| Subject | osilodrostat | Small molecule | 10 mg | Oral |